Medical treatment of recurrent meningiomas

Expert Review of Neurotherapeutics

Volumn 11, Issue 10, 2011, Pages 1425-1432

  Chamberlain, Marc C ^a   Barnholtz Sloan, Jill S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapy; hormonal therapy; recurrent intracranial meningiomas; targeted therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DILTIAZEM; DOXORUBICIN; ERLOTINIB; GEFITINIB; HYDROXYUREA; IFOSFAMIDE; IMATINIB; IRINOTECAN; MATUZUMAB; MEGESTROL ACETATE; MIFEPRISTONE; NIFEDIPINE; NIMOTUZUMAB; OCTREOTIDE; PANITUMUMAB; PASIREOTIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ALPHA INTERFERON; SOMATOSTATIN; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; UNINDEXED DRUG; VATALANIB; VERAPAMIL; VINCRISTINE;

ANEMIA; CANCER HORMONE THERAPY; CANCER SURGERY; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GLIOMA; HEAD AND NECK CANCER; HUMAN; MALIGNANT MENINGIOMA; MENINGIOMA; MOLECULARLY TARGETED THERAPY; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; REVIEW; STEREOTACTIC TREATMENT;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MOLECULAR TARGETED THERAPY;

EID: 80053519464     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.38     Document Type: Review

References (59)

1. Central Brain Tumor Registry of the USA. Statistical Report: Primary Brain Tumors in the United States, 2004-2006. Central Brain Tumor Registry of the USA, IL, USA (2010)
2. Modan B, Baidatz D, Mart H, Steinitz R, Levin SG. Radiation-induced head and neck tumours. Lancet 1, 277-279 (1974)
3. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat. Res. 163(4), 424-432 (2005) (Pubitemid 40404651)
4. Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. Cancer incidence in atomic bomb survivors. Part IV: comparison of cancer incidence and mortality. Radiat. Res. 137(2 Suppl.), S98-S112 (1994) (Pubitemid 24060248)
5. Shintani T, Hayakawa N, Hoshi M et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J. Radiat. Res. (Tokyo) 40(1), 49-57 (1999) (Pubitemid 129546054)
6. Ron E, Modan B, Boice JD Jr et al. Tumors of the brain and nervous system after radiotherapy in childhood. N. Engl. J. Med. 319(16), 1033-1039 (1988)
7. Longstreth WT Jr, Phillips LE, Drangsholt M et al. Dental X-rays and the risk of intracranial meningioma: a population-based case-control study. Cancer 100(5), 1026-34 (2004) (Pubitemid 38222864)
8. Claus EB, Black PM, Bondy M et al. Exogenous hormones and meningioma risk: what do we tell our patients? Cancer 110(3), 471-476 (2007) (Pubitemid 47106134)
9. Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6, 152 (2006)
10. Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int. J. Cancer 119(5), 1152-1157 (2006) (Pubitemid 44116925)
11. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am. J. Epidemiol. 164(7), 629-636 (2006) (Pubitemid 44453491)
12. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J. Neurooncol. 99, 307-318 (2010)
13. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J. Neurooncol. 99(3), 307-314 (2010)
14. Lee Y, Liu J, Patel S et al. Genomic landscape of meningiomas. Brain Pathol. 20(4), 751-62 (2010)
15. Perez-Magan E, Rodriquez de Lopez A, Ribalta T et al. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol. 12(12), 1278-1290 (2010)
16. Goldsmith B, McDermott MW. Meningioma. Neurosurg. Clin. N. Am. 17, 111-120, vi (2006)
17. McMullen KP, Stieber VW. Meningioma: current treatment options and future directions. Curr. Treat. Options Oncol. 5, 499-509 (2004) (Pubitemid 39591809)
18. Ragel B, Jensen RL. New approaches for the treatment of refractory meningiomas. Cancer Control. 10, 148-158 (2003) (Pubitemid 36437821)
19. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J. Neurooncol. 99(3), 365-378 (2006)
20. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 363, 1535-1543 (2004) (Pubitemid 38596834)
21. Rogers L, Mehta M. Role of radiation therapy in treating intracranial meningiomas. Neurosurg. Focus 23(4), E4 (2007)
22. Elia AE, Shih HA, Loeffler JS. Stereotactic radiation treatment for benign meningiomas. Neurosurg. Focus 23(4), E5 (2007)
23. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr. Neurol. Neurosci. Rep. 9(3), 231-40 (2009)
24. Grunberg SM, Wells M, Russell CA et al. Long term administration of mifreprisone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 24(8), 727-33 (2006) (Pubitemid 44949876)
25. Grunberg SM, Weiss M. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J. Neurooncol. 8, 61-65 (1990) (Pubitemid 20117355)
26. Grunberg SM, Rankin C, Townsend J et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc. Am. Soc. Clin. Oncol. 20, 56a (2001) (Abstract 222)
27. Goodwin JW, Crowley J, Eyre HJ et al. A Phase II evaluation of tamoxifen unresectable or refractory meningiomas: a Southwest Oncology Group Study. J. Neurooncol. 15, 73-77 (1993)
28. McCutcheon IE, Flyvbjerg A, Hill H et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J. Neurosurg. 94, 487-492 (2001) (Pubitemid 32786030)
29. Kaba SE, DeMonte F, Bruner JM et al. The treatment of recurrent unresectable and malignant meningiomas with interferon a-2B. Neurosurg. 40, 271-275 (1997) (Pubitemid 27045087)
30. Chamberlain MC, Glantz MJ. a-interferon for recurrent WHO grade I intracranial meningiomas. Cancer 113, 2146-2151 (2008)
31. Schrell UM, Ritting MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J. Neurosurg. 86(5), 845-852 (1997) (Pubitemid 27187688)
32. Schrell UM, Ritting MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg. 86, 840-844 (1997) (Pubitemid 27187687)
33. Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br. J. Neurosurg. 18, 495-499 (2004) (Pubitemid 40076195)
34. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J. Neurooncol. 49(2), 165-170 (2004)
35. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J. Neurosurg. 97, 341-346 (2002) (Pubitemid 34827334)
36. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J. Clin. Neurosci. 9(2), 156-158 (2002) (Pubitemid 34464585)
37. Hahn BM, Schrell UMH, Sauer R et al. Prolonged oral hydroxyurea and concurrent 3f-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J. Neurooncol. 74, 157-165 (2005) (Pubitemid 41478912)
38. Loven D, Hardoff R, Sever ZB et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J. Neurooncol. 67, 221-226 (2004) (Pubitemid 38418272)
39. Swinnen LJ, Renkin C, Rushing EJ et al. Phase 2 study of hydroxyurea for unresectable meningioma (Southwest Oncology group S9811). Proc. Am. Soc. Clin. Oncol. 27, 102s (2009) (Abstract 2063)
40. Chamberlain MC, Johnston SA. Hydroxyurea for recurrent surgery and radiation refractory meningioma. Neuro Oncol. 12 (Suppl. 4), iv36-iv57 (2010) (Abstract OT-04)
41. Ragel BT, Couldwell WT, Wurster RD, Jensen RL. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg. Focus 23(4), E10 (2007)
42. Chamberlain MC, Tsao-Wei D, Groshen S. Temozolomide for treatment resistant recurrent meningioma. Neurology 62(7), 1210-1212 (2004) (Pubitemid 38456523)
43. Gupta V, Su YS, Samuelson CG et al. CPT-11: a potential new chemotherapy for atypical or malignant meningiomas. J. Neurosurg. 106(3), 455-462 (2007) (Pubitemid 46354300)
44. Chamberlain MC, Tsao-Wei D, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J. Neurooncol. 78(3), 271-276 (2006) (Pubitemid 44018821)
45. Chamberlain MC. Malignant meningiomas: adjunct combined modality therapy. J. Neurosurg. 84, 733-736 (1996) (Pubitemid 26120085)
46. Hanft S, Canoll P, Bruce JN. A review of malignant meningioma: diagnosis, characteristics, and treatment. J. Neurooncol. 99(3), 433-443 (2010)
47. Johnson M, Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J. Neuropathol. Exp. Neurol. 64, 1029-1036 (2005)
48. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J. Neurooncol. 99(3), 315-324 (2010)
49. Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res 12, 4899-4907 (2006) (Pubitemid 44338577)
50. Wen PY, Yung WKA, Lamborn KR et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 11(6), 853-860 (2009)
51. Raizer JJ, Abrey LE, Lassman AB et al. A Phase I trial of erlotinib in patients with non-progressive glioblastoma multiforme post-radiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12(1), 87-94 (2010)
52. Crombet T. Torres O. Rodriguez V et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 20, 131-136 (2001) (Pubitemid 32679501)
53. Arena S, Barbieri F, Thellung S et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J. Neurooncol. 66, 155-166 (2004) (Pubitemid 38258370)
54. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with Sandostatin. Neurology 69, 969-973 (2007) (Pubitemid 47366049)
55. Johnson DR, Kimmel DW, Burch PA et al. Phase II study of octreotide in recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 12(Suppl. 4), iv36-iv57 (2010) (Abstract OT-24)
56. Hammond S, Norden A, Drappatz J et al. Phase II study of monthly pasireotide LAR (SOM230c) for recurrent or progressive meningioma. Neuro Oncol. 12(Suppl. 4), iv69-iv68 (2010) (Abstract OT-12)
57. Kaley TJ, Wen PY, Schiff D et al. Phase II trial of sunitinib (SU011248) for recurrent meningioma. Neuro Oncol. 12(Suppl. 4), iv69-iv68 (2010) (Abstract OT-27)
58. Raizer J, Grimm S, Chandler J et al. A Phase II study trial of PTK787/ZK 222584 (PTK787) in recurrent or progressive meningiomas. Neuro Oncol. 12(Suppl. 4), iv36-iv57 (2010) (Abstract NO-62)
59. National Comprehensive Cancer Network (NCCN) www.nccn.org/index.asp